Comparative Pharmacology
Head-to-head clinical analysis: BRENZAVVY versus DAPAGLIFLOZIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRENZAVVY versus DAPAGLIFLOZIN.
BRENZAVVY vs DAPAGLIFLOZIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brenzavvy (bexagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. It also promotes osmotic diuresis and may improve cardiovascular and renal outcomes through hemodynamic and metabolic effects.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing renal glucose reabsorption and lowering blood glucose.
Recommended dose: 1 tablet (200 mg finerenone) orally once daily.
10 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, supporting once-daily dosing.
Clinical Note
moderateDapagliflozin + Gatifloxacin
"Dapagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateDapagliflozin + Rosoxacin
"Dapagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateDapagliflozin + Levofloxacin
"Dapagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateDapagliflozin + Trovafloxacin
"Dapagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.9 hours (range 10-16 hours) for dapagliflozin, supporting once-daily dosing. At steady state, effective half-life is ~23 hours due to metabolite.
Approximately 65% of the dose is excreted renally as unchanged drug, and about 35% is eliminated via biliary/fecal routes as metabolites.
Primarily renal and fecal: ~75% of dose excreted in urine (as unchanged dapagliflozin and glucuronide conjugates), ~21% in feces. Biliary elimination is negligible.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor